Kardigan filed for a Nasdaq IPO targeting net proceeds around $320 million, as the cardio-focused company prepares Phase 2b/3 and Phase 2 studies across genetic dilated cardiomyopathy and calcific aortic valve stenosis. The financing plan also includes an antisense oligonucleotide program for hypertension-linked indications. Parabilis Medicines priced an upsized $670 million IPO at $20 per share, positioning the oncology developer for broader clinical and platform investment. The offering is framed as a record for venture-backed biopharma listings in 2026. At the same time, Summit Therapeutics withdrew plans for a $500 million offering, citing market conditions—an example of how capital markets are still highly selective on timing and story. Together, the IPO and withdrawal moves highlight a split: strong demand for credible late-stage and well-capitalized narratives, alongside heightened sensitivity to window-of-opportunity risk.